Valuation: Seres Therapeutics, Inc.

Market Cap 12.64M 11.51M 10.61M 9.65M 18.11M 1.17B 19.03M 129M 51.32M 639M 47.43M 46.43M 2.01B P/E 2026 *
-0.26x
P/E 2027 * -0.64x
Enterprise Value 12.64M 11.51M 10.61M 9.65M 18.11M 1.17B 19.03M 129M 51.32M 639M 47.43M 46.43M 2.01B EV / Sales 2026 *
6.32x
EV / Sales 2027 * 30x
Free-Float
88.79%
Yield 2026 *
-
Yield 2027 * -
11-05 Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-04 Seres Therapeutics, Inc. Progresses Plans For Next Study Evaluating SER-155 For Prevention Of Immune Checkpoint Inhibitor-Related Enterocolitis CI
11-04 Seres Therapeutics, Inc. Reports impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2026 CI
11-03 Seres Therapeutics Announces Publication Of SER-155 Phase 1b Results In Nature Medicine Showing Reduced Bloodstream Infections In Allogeneic Hematopoietic Cell Transplantation Recipients CI
10-27 Seres Therapeutics, Inc. Announces Resignation of Marella Thorell as Chief Financial Officer, Effective November 15, 2026 CI
10-27 Seres Therapeutics, Inc. Announces Resignation of Marella Thorell as Executive Vice President, Effective November 15, 2026 CI
10-16 Chinese automakers make tech-led pitch for Europe's premium car market RE
10-15 Seres Therapeutics, Inc. Announces Preclinical Data for SER-428, an Investigational Live Biotherapeutic Product Designed to Reduce Risk of Bloodstream Infections CI
09-21 Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from S&P Global BMI Index CI
08-14 Seres Therapeutics Files $300 Million Mixed Shelf MT
08-05 Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-09 Seres Therapeutics Announces Early Clinical Data Showing Potential For SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis CI
07-08 Seres Therapeutics, Inc. - Special Call

Last Transcript: Seres Therapeutics, Inc.

1 day-6.77%
1 week-11.43%
Current month-29.94%
1 month-46.09%
3 months-72.81%
6 months-84.60%
Current year-91.67%
1 week 1.2
Extreme 1.201
1.7
1 month 1.2
Extreme 1.201
2.26
Current year 1.2
Extreme 1.201
16.42
1 year 1.2
Extreme 1.201
18.86
3 years 1.2
Extreme 1.201
41
5 years 1.2
Extreme 1.201
233.8
10 years 1.2
Extreme 1.201
770
Manager TitleAgeSince
Chief Executive Officer 70 02/03/2026
President 51 02/03/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 02/03/2026
Director/Board Member 50 15/01/2019
Director/Board Member 80 01/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-82 0.0008%
17/8/26 Sell

Director

-263 0.0027%
17/8/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
-6.77%-11.43%-93.00%-94.07% 12.64M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.91%-2.47%+20.46%+153.08% 40B
Weighted average by Cap. -1.48%-2.04%+31.83%+155.16%

Financials

2026 *2027 *
Net sales 2M 1.82M 1.68M 1.53M 2.86M 185M 3.01M 20.43M 8.12M 101M 7.5M 7.35M 317M 422K 384K 354K 322K 604K 39.08M 635K 4.31M 1.71M 21.34M 1.58M 1.55M 66.99M
Net income -47.4M -43.17M -39.78M -36.19M -67.89M -4.39B -71.35M -484M -192M -2.4B -178M -174M -7.52B -52.83M -48.12M -44.34M -40.33M -75.67M -4.89B -79.53M -540M -214M -2.67B -198M -194M -8.39B
Net Debt - -
Projected Income Statement - Annual - Seres Therapeutics, Inc.
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
20/11/26 US$1.240 -6.77% 57,062
19/11/26 US$1.330 -7.64% 54,689
18/11/26 US$1.440 +2.13% 42,969
17/11/26 US$1.410 0.00% 55,575
16/11/26 US$1.410 +0.71% 186,619
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Seres Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.240USD
Average target price
17.00USD
Spread / Average Target
+1,270.97%
  1. Stock Market
  2. Stocks
  3. MCRB Stock